A
Andrew J. Mackin
Researcher at Mississippi State University
Publications - 92
Citations - 1778
Andrew J. Mackin is an academic researcher from Mississippi State University. The author has contributed to research in topics: Whole blood & Aspirin. The author has an hindex of 23, co-authored 89 publications receiving 1498 citations. Previous affiliations of Andrew J. Mackin include Cornell University & University of Guelph.
Papers
More filters
Journal ArticleDOI
Treatment of Canine Hemangiosarcoma: 2000 and Beyond
TL;DR: The use of multimodality therapy incorporating innovative treatment modalities may offer the best therapeutic option for dogs affected with HSA.
Journal ArticleDOI
Aetiology and diagnosis of persistent nasal disease in the dog: a retrospective study of 42 cases
TL;DR: Anterograde rhinoscopy and retroflexed endoscopy had higher specificity and sensitivity than radiology for the diagnosis of neoplasia, inflammatory rhinitis, aspergillosis and foreign bodies.
Journal ArticleDOI
Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma.
Craig A. Clifford,Dez Hughes,Matthew W. Beal,Andrew J. Mackin,Carolyn J. Henry,Frances S. Shofer,Karin U. Sorenmo +6 more
TL;DR: Healthy client-owned dogs with HSA were significantly more likely to have detectable concentrations of plasma VEGF compared to healthy dogs with hemangiosarcoma, and 1 dog had undetectable V EGF during chemotherapy that subsequently increased with disease progression.
Journal ArticleDOI
Oral Cyclosporine Treatment in Dogs: A Review of the Literature
Todd M. Archer,Dawn M. Boothe,Vernon C. Langston,Claire Fellman,Kari V. Lunsford,Andrew J. Mackin +5 more
TL;DR: Therapeutic drug monitoring (TDM) can facilitate therapeutic success by guiding dose adjustments on an individualized basis, and is recommended in cases that do not respond to initial oral dosing, or during treatment of severe, life‐threatening diseases for which a trial‐and‐error approach to dose adjustment is too risky.
Journal ArticleDOI
ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.
James W. Swann,Oliver A. Garden,Claire L. Fellman,Barbara Glanemann,Robert Goggs,Dana N. LeVine,Andrew J. Mackin,Nathaniel T. Whitley +7 more
TL;DR: A novel tool for evaluation of evidence quality was developed, using it to assess study design, diagnostic criteria, explanation of treatment regimens, and validity of statistical methods, which led to a set of clinical recommendations regarding treatment of IMHA in dogs.